Despite the underlying mechanisms of such findings remaining a matter of theoretical postulation [60, 110–112, 124], the contribution of CVOTs as new evidence to the diabetes treatment armamentarium highlights a new era of standard treatment practices; endorsed by international guidelines such as ADA and EASD, to highlight the potential of SGLT2 inhibitors and GLP-1 RAs to improve cardiorenal outcomes for patients with T2D [38, 40]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.